A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs LTG-001 (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Latigo Biotherapeutics
- 21 Jan 2025 New trial record